Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Ensign Group

ENSG Healthcare Unknown Updated July 31, 2026
$178.21
52W $141.58 – $218.00
58/100
$10.38B
27.1
0.69
AI Committee Verdict
Buy
Conviction: Moderate · 71% agreement · 7 analysts
+8.7%
-6.0%
1.45:1
Moderate

Is ENSG Bullish or Bearish?

Bullish. Innellis AI committee rates Ensign Group (ENSG) Buy with a composite score of 58/100 , based on 7 analysts with 71% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +16.83 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -3.17 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Some positive signals exist — low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.

Bull & Bear Case

Bull Case
  • ROE of 16.5% shows genuine earnings power backing the valuation — Value
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
  • Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock — Risk
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • P/E of 27.3 is moderate-to-rich — Value
  • Price-to-book of 4.5x prices in significant intangible value — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
58/100
Agreement
71%
Analysts
7
Conviction
Moderate
Sector Rank
Top 23%
of 93 Healthcare peers
Value Analyst neutral
54 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 16.5% shows genuine earnings power backing the valuation
− P/E of 27.3 is moderate-to-rich
Growth Analyst neutral
50 / 100 · Moderate confidence
Moderate growth -- present but not remarkable
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ MACD histogram positive -- bullish momentum
Risk Analyst bullish
80 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst neutral
60 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 58.2 to 58.2.

Analyst-level changes:
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).
  • Technical Analyst: stance neutral->bullish; score 54->61 (+8).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
61.0
Neutral
MACD Histogram
0.986
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Lh Ll
Support
$167.57
Resistance
$193.68
Bollinger %B
0.80
Inside Bands
Price vs Moving Averages
EMA 9
$176.56 Above
EMA 21
$172.56 Above
EMA 50
$171.51 Above
EMA 200
$175.64 Above

Fundamental Analysis

Valuation
58
Growth
68
Profitability
0
Financial Health
57
Cash Flow
37
Valuation
P/E Ratio 27.1×
P/B Ratio 4.23×
PEG Ratio 1.71
Dividend Yield 0.00%
52W High $218.00
52W Low $141.58
Quality & Growth
ROE 15.4%
ROA 6.3%
Gross Margin 14.1%
Operating Margin 8.5%
Revenue Growth YoY
Debt / Equity 0.92
AI Fundamental Assessment
P/E ratio of 27.1 (moderate relative to a 15-40x range); Price-to-book of 4.2x; PEG ratio of 1.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.2%; Return on assets of 0.1%; Net margin of 0.1%; Gross margin of 0.1%; Current ratio of 1.21 (tight short-term liquidity); Debt-to-equity of 0.92; Free cash flow margin of 0.7% (thin cash generation); Free cash flow per share is positive (7.23); Most recent quarter beat estimates by 2.2%; EPS growth accelerating (+1.6% -> +3.8% QoQ); Average YoY EPS growth of 20.8%; Analyst estimates rising over recent quarters
Get the Full ENSG Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore ENSG Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime